218 related articles for article (PubMed ID: 36930242)
1. Molecular subtypes based on PANoptosis-related genes and tumor microenvironment infiltration characteristics in lower-grade glioma.
Abulaiti A; Maimaiti A; Yiming N; Fu Q; Li S; Li Y; Wang Y; Zhou Q
Funct Integr Genomics; 2023 Mar; 23(2):84. PubMed ID: 36930242
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
3. Identification of PANoptosis-related predictors for prognosis and tumor microenvironment by multiomics analysis in glioma.
Sun F; Liao M; Tao Z; Hu R; Qin J; Tao W; Liu W; Wang Y; Pi G; Lei J; Bao W; Dong Z
J Cancer; 2024; 15(9):2486-2504. PubMed ID: 38577605
[TBL] [Abstract][Full Text] [Related]
4. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis identifies genetic and molecular factors associated with prognostic clusters of PANoptosis in glioma, kidney and melanoma cancer.
Mall R; Kanneganti TD
Sci Rep; 2023 Nov; 13(1):20962. PubMed ID: 38017056
[TBL] [Abstract][Full Text] [Related]
6. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer.
Liu Z; Sun L; Peng X; Zhu J; Wu C; Zhu W; Huang C; Zhu Z
Apoptosis; 2024 Jun; 29(5-6):799-815. PubMed ID: 38347337
[TBL] [Abstract][Full Text] [Related]
7. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
8. Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
Yu H; Gong M; Qi J; Zhao C; Niu W; Sun S; Li S; Hong B; Qian J; Wang H; Chen X; Fang Z
BMC Cancer; 2022 Aug; 22(1):885. PubMed ID: 35964070
[TBL] [Abstract][Full Text] [Related]
9. Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma.
Shi X; Gao X; Liu W; Tang X; Liu J; Pan D; Duan X; Jin Y; Ren W; Yang L; Liu W
Oncol Res; 2023; 31(4):569-590. PubMed ID: 37415742
[TBL] [Abstract][Full Text] [Related]
10. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
11. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer.
Pan H; Pan J; Li P; Gao J
Clin Immunol; 2022 May; 238():109019. PubMed ID: 35470064
[TBL] [Abstract][Full Text] [Related]
12. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
13. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma.
Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B
Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059
[TBL] [Abstract][Full Text] [Related]
14. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
15. The PANoptosis-related signature indicates the prognosis and tumor immune infiltration features of gliomas.
Song J; Xu Z; Fan Q; Sun Y; Lin X
Front Mol Neurosci; 2023; 16():1198713. PubMed ID: 37501725
[TBL] [Abstract][Full Text] [Related]
16. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
17. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
18. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
19. Identification of natural killer cell-related characteristics to predict the clinical prognosis and immune microenvironment of patients with low-grade glioma.
Sun F; Lv H; Feng B; Sun J; Zhang L; Dong B
Aging (Albany NY); 2023 Jul; 15(13):6264-6291. PubMed ID: 37405952
[TBL] [Abstract][Full Text] [Related]
20. Systematic Analysis of a Pyroptosis-Related Signature to Predict the Prognosis and Immune Microenvironment of Lower-Grade Glioma.
He Y; Cai Y; Liu J; Ding H; Li X; Tian S; Li Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
